Ms Davies has over 20 years’ professional experience in virus research and molecular biology, with the last 15 years focused on the development and manufacture of the oncolytic virotherapy agent CAVATAK at Viralytics. At ImmVirX she has the lead role in driving CMC operations, including project management of viral seed and cell bank production, and oversight of process and analytical assay development, culminating in GMP drug substance manufacture.
In her most recent years at Viralytics, she served as Manager, Manufacturing Science. In that role, she was responsible for the technical oversight of external manufacturing of both raw materials and drug substances at GMP-contract manufacturing sites located in the USA and the UK.
Following the acquisition of Viralytics by Merck and Co, Ms Davies played a key role in the technical transfer of the CAVATAKTM manufacturing and analytical testing programs. As part of this effort, she joined the project team at the Merck West Point Facility in Pennsylvania, USA for the continued on-site technical support of the drug substance manufacturing process and as an analytical testing SME